首页> 外文会议>World Congress on Particle Technology >Studies on the preparation, characterization and intracellular kinetics of JD27-loaded human serum albumin nanoparticles
【24h】

Studies on the preparation, characterization and intracellular kinetics of JD27-loaded human serum albumin nanoparticles

机译:JD27负载人血清白蛋白纳米粒子的制备,表征和细胞内动力学研究

获取原文

摘要

JD27 is a derivatives of active ingredient extracted from Rabdosia which includes a functional group of 1,2,3-Triazoles. It is considered as a promising anti-cancer drug candidate because of its low toxicity and broad-spectrum anti-cancer activity. However, the clinical application of JD27 has been limited by its poor solubility. Albumin is an attractive macromolecular carrier, which has been widely used in nanoparticle preparation. Compared with other drug delivery systems, drug-loaded albumin nanoparticles showed a series of advantages such as solubilization of hydrophobic drug, biodegradable, biocompatible and so on. In this study, JD27-loaded human serum albumin nanoparticles (JD27-NPs) were obtained using an established desolvation method and they were characterized by particle size, zeta potential, encapsulation efficiency, surface morphology and in vitro drug release studies. In addition, their cytotoxic activities, intracellular kinetics and cell membranes permeability were evaluated in EC-9706 cells. The experiment results showed that the particle size, zeta potential, and encapsulation efficiency were (276.-5±8.26) nm, (-41.4±7.21) mV and 82.2%±5.09%, respectively. SEM images suggest that JD27-NPs were a round shape, similar uniform size and smooth surface. Drug release studies indicated JD27-NPs had the properties of sustained release. The results of cytotoxic activities suggest that antitumor efficacy of JD27-NPs is higher than JD27 in EC-9706 cells. According to the results of intracellular kinetics, the concentration of JD27-NPs in the cell could reach the peak concentration after 2 hour and gradually decreases with time lasted. The AUC0-12h and MRT of JD27-NPs are significantly higher than that in JD27 (P<0.05). JD27-NPs have advantages to keep a higher and steadier intracellular concentration than JD27 which shows JD27-NPs have priority in application. The results of Hoechst 33258 staining suggested that the permeability of the cells membrane can be changed with the different concentration and treatment time of JD27. In conclusion, albumin nanopaticles may act as a useful and safe carrier for JD27.JD27-NPs will be a promising formulation for cancer therapy in future.
机译:JD27是从Rabdosia提取的活性成分的衍生物,其包括1,2,3-三唑的官能团。由于其低毒性和广谱抗癌活动,它被认为是有前途的抗癌药物候选者。然而,JD27的临床应用受其溶解度差的限制。白蛋白是一种有吸引力的大分子载体,已广泛用于纳米颗粒制备。与其他药物递送系统相比,载药白蛋白纳米颗粒显示出一系列优点,例如疏水药,可生物降解,生物相容性等。在该研究中,使用已建立的去溶化方法获得JD27负载的人血清白蛋白纳米颗粒(JD27-NPS),其特征在于粒径,Zeta电位,包封效率,表面形态和体外药物释放研究。此外,在EC-9706细胞中评价其细胞毒性活性,细胞内动力学和细胞膜渗透性。实验结果表明,粒度,ζ电位和封装效率分别为(276.-5±8.26)Nm,(-41.4±7.21)mV,分别为82.2%±5.09%。 SEM图像表明JD27-NPS是圆形,相似均匀的尺寸和光滑的表面。药物释放研究表明JD27-NPS具有持续释放的性质。细胞毒性活性的结果表明,JD27-NPS的抗肿瘤功效高于EC-9706细胞中的JD27。根据细胞内动力学的结果,细胞中的JD27-NPS的浓度可以在2小时后达到峰浓度并随时间逐渐减少。 JD27-NP的AUC0-12H和MRT显着高于JD27(P <0.05)。 JD27-NPS具有比JD27保持更高和稳定的细胞内浓度的优点,所述JD27显示JD27-NPS优先于应用中。 Hoechst 33258染色的结果表明,通过JD27的不同浓度和治疗时间可以改变细胞膜的渗透性。总之,白蛋白纳米型可以用作JD27.JD27-NPS的有用和安全的载体将是未来癌症治疗的有希望的制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号